195 related articles for article (PubMed ID: 29263719)
1. The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.
Cioppi F; Cianferotti L; Masi L; Giusti F; Brandi ML
Clin Cases Miner Bone Metab; 2017; 14(2):123-130. PubMed ID: 29263719
[TBL] [Abstract][Full Text] [Related]
2. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
Ramundo V; Del Prete M; Marotta V; Marciello F; Camera L; Napolitano V; De Luca L; Circelli L; Colantuoni V; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A;
Clin Endocrinol (Oxf); 2014 Jun; 80(6):850-5. PubMed ID: 24443791
[TBL] [Abstract][Full Text] [Related]
3. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
4. From somatostatin to octreotide LAR: evolution of a somatostatin analogue.
Anthony L; Freda PU
Curr Med Res Opin; 2009 Dec; 25(12):2989-99. PubMed ID: 19842996
[TBL] [Abstract][Full Text] [Related]
5.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors.
Graf A; Welch J; Bansal R; Mandl A; Parekh VI; Cochran C; Levy E; Nilubol N; Patel D; Sadowski S; Jha S; Agarwal SK; Millo C; Blau JE; Simonds WF; Weinstein LS; Del Rivero J
J Endocr Soc; 2022 Oct; 6(10):bvac122. PubMed ID: 36111275
[TBL] [Abstract][Full Text] [Related]
7. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
10. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
11. Clinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1.
Jhawar S; Lakhotia R; Suzuki M; Welch J; Agarwal SK; Sharretts J; Merino M; Ahlman M; Blau JE; Simonds WF; Del Rivero J
Endocrinol Diabetes Metab Case Rep; 2019 Aug; 2019():. PubMed ID: 31480016
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review.
La Salvia A; Sesti F; Grinzato C; Mazzilli R; Tarsitano MG; Giannetta E; Faggiano A
Pharmaceuticals (Basel); 2021 Oct; 14(10):. PubMed ID: 34681263
[TBL] [Abstract][Full Text] [Related]
13. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
Enzler T; Fojo T
Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.
Wang Y; Wang W; Jin K; Fang C; Lin Y; Xue L; Feng S; Zhou Z; Shao C; Chen M; Yu X; Chen J
Oncol Lett; 2017 Mar; 13(3):1165-1174. PubMed ID: 28454229
[TBL] [Abstract][Full Text] [Related]
15. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST
Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704
[TBL] [Abstract][Full Text] [Related]
16. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
Ström T; Kozlovacki G; Myrenfors P; Almquist M
Patient Prefer Adherence; 2019; 13():1799-1807. PubMed ID: 31695341
[TBL] [Abstract][Full Text] [Related]
17. A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors.
Seo C; Horodniceanu E; Shah R; Goldstein G; Ray D; Bennett B; Phan A; McCarrier K
Support Care Cancer; 2022 Jul; 30(7):6307-6316. PubMed ID: 35476113
[TBL] [Abstract][Full Text] [Related]
18. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
Pusceddu S; Prinzi N; Raimondi A; Corti F; Buzzoni R; Di Bartolomeo M; Seregni E; Maccauro M; Coppa J; Milione M; Mazzaferro V; de Braud F
Tumori; 2019 Apr; 105(2):113-120. PubMed ID: 29714658
[TBL] [Abstract][Full Text] [Related]
19. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
[TBL] [Abstract][Full Text] [Related]
20. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
Challis BG; Casey RT; Grossman A; Newell-Price J; Newey P; Thakker RV
Clin Endocrinol (Oxf); 2019 Dec; 91(6):708-715. PubMed ID: 31505044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
